1 completed, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Non Clear Cell Renal Cell Carcinoma (nccRCC): new trials by email Literature Review of Non Clear Cell Renal Cell Carcinoma (nccRCC) trials Research Report on Non Clear Cell Renal Cell Carcinoma (nccRCC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors Darlifarnib, Cabozantinib, Adagrasib - Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC) | Phase 1 | Recruiting | Kura Oncology, Inc. | 300 | 2023-10-18 | 2026-10-14 |
| A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease lenvatinib, everolimus - Non Clear Cell Renal Cell Carcinoma (nccRCC) | Phase 2 | Completed | Eisai Inc. | 41 | 2017-02-20 | 2023-01-17 |
Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Kidney Neoplasms (1) · Neoplasm Metastasis (1)
Neoplasms (2) · Adenocarcinoma (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Kidney Diseases (1)
Everolimus (1) · adagrasib (1) · cabozantinib (1) · lenvatinib (1)
Eisai Inc. (1) · Kura Oncology, Inc. (1)
United States (2) · France (1) · Germany (1) · Italy (1) · Spain (1)